Document:

Exhibit
4.4

 

DESCRIPTION
OF SECURITIES

 

REGISTERED
UNDER SECTION 12 OF THE EXCHANGE ACT

 

Provectus
Biopharmaceuticals, Inc. (the “Company,” “Provectus”, “we” or “our”) has one class
of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our Common
Stock.

 

Description
of Common Stock

 

The
following description of our Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety
by reference to our Certificate of Incorporation, as amended (the “Certificate of Incorporation”), and our Bylaws, as amended
(the “Bylaws”), each of which is incorporated by reference as an exhibit to the Annual Report on Form 10-K, of which this
Exhibit is a part. We encourage you to read our Certificate of Incorporation, our Bylaws and the applicable provisions of the Delaware
General Corporation Law, for additional information.

 

Authorized
Shares of Capital Stock

 

Our
authorized capital stock consists of 1,000,000,000 shares of common stock, $0.001 par value per share (“Common Stock”), and
25,000,000 shares of preferred stock, $0.001 par value per share (“Preferred Stock”). As of December 31, 2021, 419,447,119
shares of Common Stock were issued and outstanding. The outstanding shares of our Common Stock are duly authorized, validly issued, fully
paid, and nonassessable.

 

Voting
Rights

 

Holders
of Common Stock are entitled to one vote per share on all matters voted on by the stockholders, including the election of directors.
Our Common Stock does not have cumulative voting rights.

 

Dividend
Rights

 

Subject
to the rights of holders of outstanding shares of Preferred Stock, if any, the holders of Common Stock are entitled to receive dividends,
if any, as may be declared from time to time by the Company’s Board of Directors (the “Board”) in its discretion out
of funds legally available for the payment of dividends.

 

Liquidation
Rights

 

In
the event of our dissolution, liquidation or winding up, holders of our Common Stock are entitled to share ratably in any assets remaining
after the satisfaction in full of the prior rights of creditors and the aggregate liquidation preference of any Preferred Stock then
outstanding.

 

    	 

    	 

    

 

Other
Rights and Preferences

 

Holders
of our Common Stock do not have any conversion, redemption, sinking fund or preemptive rights.

 

Certain
Anti-Takeover Effects

 

Provisions
of our Certificate of Incorporation and Bylaws may delay or discourage transactions involving an actual or potential change of control
or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions
that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price
of our Common Stock. Among other things, our Certificate of Incorporation and Bylaws will:

 

	 	●	permit
    our Board to issue up to 25,000,000 shares of Preferred Stock, with any rights, preferences, and privileges as they may designate;
	 	 	 
	 	●	provide
    that all vacancies on our Board, including as a result of newly created directorships, may, except as otherwise required by law,
    be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
	 	 	 
	 	●	require
    that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not
    be taken by written consent;
	 	 	 
	 	●	provide
    that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors
    at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of
    a stockholder’s notice;
	 	 	 
	 	●	not
    provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of Common Stock entitled to vote in
    any election of directors to elect all of the directors standing for election; and
	 	 	 
	 	●	provide
    that special meeting of our stockholders may be called only by the Board or by such person or persons requested by a majority
    of the Board to call such meetings.

 

Preferred
Stock

 

The
rights, preferences, and privileges of the holders of our Common Stock are subject to, and may be adversely affected by, the rights
of the holders of shares of any series of Preferred Stock that we have designated and issued or may designate and issue in the
future. Under our Certificate of Incorporation, we are authorized to issue up to 25,000,000 shares of Preferred Stock, from time to time
in one or more series, in any manner permitted by law, as determined from time to time by our Board, and stated in the resolution or
resolutions providing for the issuance of such shares adopted by our Board. Without limiting the generality of the foregoing, shares
in such series shall have voting powers, full or limited, or no voting powers, and shall have such designations, preferences and relative,
participating, optional, or other special rights, and qualifications, limitations, or restrictions thereof, permitted by law, as shall
be stated in the resolution or resolutions providing for the issuance of such shares adopted by our Board. The number of shares of any
such series so set forth in the resolution or resolutions may be increased (but not above the total number of authorized shares of Preferred
Stock) or decreased (but not below the number of shares thereof then outstanding) by further resolution or resolutions adopted by the
Board. As of December 31, 2021, 12,373,247 and 9,218,449 shares of Series D and D-1 Preferred Stock were issued and outstanding,
respectively.

 

Series
B Convertible Preferred Stock

 

The
following summary of certain terms and provisions of the Series B Preferred Stock is subject to, and qualified in its entirety by reference
to, the terms and provisions set forth in our certificate of designation of preferences, rights and limitations of the Series B Preferred
Stock, a copy of which is filed as Exhibit 3.2 to this Annual Report on Form 10-K, of which this Exhibit is a part
(the “Certificate of Designation”).

 

    	 

    	 

    

 

Our
Series B Preferred Stock is convertible into shares of our Common Stock (subject to the beneficial ownership limitations as provided
in the related Certificate of Designation), at the Adjusted Conversion Price equal to $0.0533 per share of Common Stock, subject to adjustment
as provided in the Certificate of Designation, at any time at the option of the holder prior to the fifth anniversary of the date of
issuance, at which time all shares of outstanding Series B Preferred Stock shall automatically and without any further action by the
holder be converted into shares of our Common Stock at the then effective conversion price, provided that the holder will be prohibited
from converting Series B Preferred Stock into shares of our Common Stock if, as a result of such conversion, the holder, together with
its affiliates, would own more than 4.99% of the total number of shares of our Common Stock then issued and outstanding. However, any
holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage
shall not be effective until 61 days after such notice to us.

 

The
holders of Series B Preferred Stock will be entitled to receive cumulative dividends at the rate per share of 8% per annum of the stated
value per share, until the fifth anniversary of the date of issuance of the Series B Preferred Stock. The dividends become payable, at
our option, in either cash, out of any funds legally available for such purpose, or in shares of Common Stock, (i) upon any conversion
of the Series B Preferred Stock, (ii) on each such other date as our Board may determine, subject to written consent of the holders of
Series B Preferred Stock holding a majority of the then issued and outstanding Series B Preferred Stock, (iii) upon our liquidation,
dissolution or winding up, and (iv) upon occurrence of a fundamental transaction, including any merger or consolidation, sale of all
or substantially all of our assets, exchange or conversion of all of our Common Stock by tender offer, exchange offer or reclassification;
provided, however, that if Series B Preferred Stock is converted into shares of Common Stock at any time prior to the fifth anniversary
of the date of issuance of the Series B Preferred Stock, the holder will receive a make-whole payment in an amount equal to all of the
dividends that, but for the early conversion, would have otherwise accrued on the applicable shares of Series B Preferred Stock being
converted for the period commencing on the conversion date and ending on the fifth anniversary of the date of issuance, less the amount
of all prior dividends paid on such converted Series B Preferred Stock before the date of conversion. Make-whole payments are payable
at our option in either cash, out of any funds legally available for such purpose, or in shares of Common Stock.

 

With
respect to any dividend payments and make-whole payments paid in shares of Common Stock, the number of shares of Common Stock to be issued
to a holder of Series B Preferred Stock will be an amount equal to the quotient of (i) the amount of the dividend payable to such holder
divided by (ii) the conversion price then in effect. Because the conversion price in effect on the Price Reset Date exceeded 85% of the
average of the 45 lowest volume weighted average trading prices of the Common Stock during the period commencing on the date of issuance
of the Series B Preferred Stock and ending on the Price Reset Date, the conversion price was reset to the Adjusted Conversion Price and
shall be further subject to adjustment as provided in the Certificate of Designation. In either case, if a holder of Series B Preferred
Stock converted its shares of Series B Preferred Stock prior to any such price reset event, then such holder was entitled to receive
shares of Common Stock equal to the difference between the conversion price and the Adjusted Conversion Price.

 

In
the event of our liquidation, dissolution, or winding up, holders of our Series B Preferred Stock will be entitled to receive the amount
of cash, securities or other property to which such holder would be entitled to receive with respect to such shares of Series B Preferred
Stock if such shares had been converted to Common Stock immediately prior to such event (without giving effect for such purposes to the
4.99% or 9.99% beneficial ownership limitation, as applicable) subject to the preferential rights of holders of any class or series of
our capital stock specifically ranking by its terms senior to the Series B Preferred Stock as to distributions of assets upon such event,
whether voluntarily or involuntarily.

 

The
holders of the Series B Preferred Stock have no voting rights, except as required by law. Any amendment to our Certificate of Incorporation,
Bylaws or Certificate of Designation that adversely affects the powers, preferences and rights of the Series B Preferred Stock requires
the approval of the holders of a majority of the shares of Series B Preferred Stock then outstanding.

 

On
August 25, 2021, all remaining shares of Series B Preferred Stock were converted into shares of Common Stock.

 

Series
D and Series D-1 Preferred Stock

 

The
rights, preferences and privileges of the Series D Convertible Preferred Stock are set forth in a Certificate of Designation of Preferences,
Rights and Limitations of Series D Convertible Preferred Stock (the “Series D Certificate of Designation”), a copy of which
is attached as Exhibit 3.3 to this Annual Report on Form 10-K. The rights, preferences and privileges of the Series D-1 Convertible Preferred
Stock are set forth in a Certificate of Designation of Preferences, Rights and Limitations of Series D-1 Convertible Preferred Stock
(the “Series D-1 Certificate of Designation”), a copy of which is attached as Exhibit 3.4 to this Annual Report on Form 10-K.

 

    	 

    	 

    

 

The
Board of Directors of the Company approved each of the Series D Certificate of Designation and Series D-1 Certificate of Designation
on June 16, 2021, and each of the Series D Certificate of Designation and Series D-1 Certificate of Designation were filed with the Delaware
Secretary of State on June 17, 2021. The Series D Certificate of Designation and Series D-1 Certificate of Designation are the same,
other than certain key differences to account solely for the different conversion ratios for the holders of 2017 Notes who did not execute
an Amendment compared to the holders of Amended 2017 Notes and the holders of 2020 Notes.

 

The
Series D Certificate of Designation established and designated 12,374,000 shares of Series D Convertible Preferred Stock. The Series
D-1 Certificate of Designation established and designated 9,441,000 shares of Series D-1 Convertible Preferred Stock.

 

The
Series D Convertible Preferred Stock and the Series D-1 Convertible Preferred Stock rank pari passu with each other.
The Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock rank senior to the Common Stock and any other class
or series of the Company’s capital stock, the terms of which do not provide that shares of such class rank senior to, or pari
passu with, the Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock as to dividends and distributions
upon a change of control transaction, or the liquidation, winding-up and dissolution of the Company.

 

The
Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock do not have any dividend preference but are entitled
to receive, on a pari passu basis, dividends, if any, that are declared and paid on the Common Stock and any other class
of the Company’s capital stock that ranks junior or on par to the Series D Convertible Preferred Stock and Series D-1 Convertible
Preferred Stock.

 

Upon
the occurrence of the liquidation, winding-up or dissolution of the Company or certain mergers, corporate reorganizations or sales of
the Company’s assets (each, a “Company Event”), holders of Series D Convertible Preferred Stock and Series D-1 Convertible
Preferred Stock will be entitled to receive a liquidation preference before any distributions are made to holders of any other class
or series of the Company’s capital stock junior to the Series D Convertible Preferred Stock and Series D-1 Convertible Preferred
Stock. If a Company Event occurs within two years of June 20, 2021 (the “Date of Issuance”), the holders of Series D Convertible
Preferred Stock and Series D-1 Convertible Preferred Stock will receive for each share of Series D Convertible Preferred Stock and Series
D-1 Convertible Preferred Stock, respectively, an amount in cash equal to the Original Issue Price (as defined in the Series D Certificate
of Designation and Series D-1 Certificate of Designation, respectively) multiplied by four. If a Company Event occurs from and after
the second anniversary of the Date of Issuance, the holders of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred
Stock will receive for each share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock, respectively, an
amount in cash equal to the Original Issue Price multiplied by six. The Original Issue Price for the Series D Convertible Preferred Stock
is $0.2862, and the Original Issue Price for the Series D-1 Convertible Preferred Stock is $2.862.

 

Holders
of shares of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will vote together with the holders of Common
Stock as a single class. Each share of Series D Convertible Preferred Stock carries the right to one vote per share. Each share of Series
D-1 Convertible Preferred Stock carries the right to 10 votes per share.

 

The
Company is not permitted to amend, alter or repeal its Certificate of Incorporation or Bylaws in a manner adverse to the relative rights,
preferences, qualifications, limitations or restrictions of the Series D Convertible Preferred Stock and Series D-1 Convertible Preferred
Stock without the affirmative vote of a majority of the votes entitled to be cast by holders of outstanding shares of Series D Convertible
Preferred Stock and Series D-1 Convertible Preferred Stock, voting together as a single class with each share of Series D Convertible
Preferred Stock and Series D-1 Convertible Preferred Stock having a number of votes equal to the number of shares of Common Stock then
issuable upon conversion of such share of Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock.

 

The
Series D Convertible Preferred Stock is convertible at the option of the holders thereof into shares of Common Stock based on a one-for-one
conversion ratio. The Series D-1 Convertible Preferred Stock is convertible at the option of the holders thereof into shares of Common
Stock based on a one-for-10 conversion ratio. The conversion ratio of the Series D Convertible Preferred Stock and Series D-1 Convertible
Preferred Stock is subject to adjustment for stock splits and combinations, recapitalizations, reclassifications, reorganizations, mergers
and consolidations. The Series D Convertible Preferred Stock and Series D-1 Convertible Preferred Stock will automatically convert into
shares of Common Stock upon the fifth anniversary of the Date of Issuance.

 

Transfer
Agent and Registrar

 

Broadridge
Financial Solutions, Inc. is the transfer agent and registrar for our Common Stock.

 

Listing

 

Our
Common Stock is traded on the OTCQB Marketplace under the trading symbol “PVCT.”Exhibit 4.1

      

      

      Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, As Amended

      

      

      The following description sets forth certain material terms and provisions of the securities of Corsair Partnering Corporation (“we,” “us” or “our”) that are registered under Section 12 of the
        Securities Exchange Act of 1934, as amended (the “Exchange Act”). The following description of our securities is not complete and may not contain all the information you should consider before investing in our securities. This description is
        summarized from, and qualified in its entirety by reference to, our amended and restated memorandum and articles of association, which are incorporated herein by reference. The summary below is also qualified by reference to the Companies Act and
        common law of the Cayman Islands.

       

      

      As of December 31, 2021, we had three classes of securities registered under the Exchange Act: our Class A ordinary shares, $0.0001 par value per share; warrants to purchase Class A ordinary
        shares; and units consisting of one Class A ordinary share and one-third of one redeemable warrant to purchase one Class A ordinary share. In addition, this Description of Securities also contains a description of our Class B ordinary shares, par
        value $0.0001 per share (“performance shares”), and our Class F ordinary shares (“founder shares”), which are not registered pursuant to Section 12 of the Exchange Act but are convertible into Class A ordinary shares. The description of the founder
        shares is necessary to understand the material terms of the Class A ordinary shares.

      

      

      Units

       

      

      Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50
        per share, subject to adjustment. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of the company’s Class A ordinary shares. This means only a whole warrant may be exercised at any given time by
        a warrant holder.

       

      

      The Class A ordinary shares and warrants began separate trading on August 23, 2021 and holders have the option to continue to hold units or separate their units into the component pieces.

      

      

      Ordinary Shares

       

      

      Ordinary shareholders of record are entitled to one vote for each share held on all matters to be voted on by shareholders. Holders of Class A ordinary shares, holders of Class B ordinary shares
        and holders of Class F ordinary shares will vote together as a single class on all matters submitted to a vote of our shareholders except as required by law. Unless specified in our amended and restated memorandum and articles of association, or as
        required by applicable provisions of the Companies Act or applicable stock exchange rules, the affirmative vote of a majority of our ordinary shares that are voted is required to approve any such matter voted on by our shareholders. Approval of
        certain actions requires a special resolution under Cayman Islands law, which requires the affirmative vote of a majority of at least two-thirds of the shareholders who attend and vote at a general meeting of the company, and pursuant to our
        amended and restated memorandum and articles of association; such actions include amending our amended and restated memorandum and articles of association and approving a statutory merger or consolidation with another company. Our board of
        directors is divided into three classes, each of which will generally serve for a term of three years with only one class of directors being elected in each year. There is no cumulative voting with respect to the election of directors, with the
        result that the holders of more than 50% of the shares voted for the election of directors can elect all of the directors. Our shareholders are entitled to receive ratable dividends when, as and if declared by the board of directors out of funds
        legally available therefor.

       

      

      
        
          

      

      Because our amended and restated memorandum and articles of association authorizes the issuance of up to 380,000,000 Class A ordinary shares, if we were to enter into our partnering transaction, we
        may (depending on the terms of such our partnering transaction) be required to increase the number of ordinary shares which we are authorized to issue at the same time as our shareholders vote on our partnering transaction to the extent we seek
        shareholder approval in connection with our partnering transaction. Our board of directors is divided into three classes with only one class of directors being elected in each year and each class (except for those directors appointed prior to our
        first annual meeting of shareholders) serving a three-year term.

       

      In accordance with the NYSE’s corporate governance requirements, we are not required to hold an annual general meeting until one year after our first fiscal year end following our listing on the
        NYSE. There is no requirement under the Companies Act for us to hold annual or general meetings or appoint directors. We may not hold an annual general meeting to elect new directors prior to the consummation of our partnering transaction.

       

      We will provide our public shareholders with the opportunity to redeem
          all or a portion of their public shares upon the completion of our partnering transaction at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account calculated as of two business days prior to the
          consummation of our partnering transaction, including interest earned on the funds held in the trust account (net of permitted withdrawals and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding
          public shares, subject to the limitations described herein. The amount in the trust account is initially anticipated to be $10.00 per public share. The per-share amount we will distribute to investors who properly redeem their shares will not be
          reduced by the deferred underwriting commissions we will pay to the underwriters. Our sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption rights with respect
          to their founder shares and public shares in connection with the completion of our partnering transaction. Unlike many special purpose acquisition companies that hold shareholder votes and conduct proxy solicitations in conjunction with their
          partnering transactions and provide for related redemptions of public shares for cash upon completion of such partnering transactions even when a vote is not required by law, if a shareholder vote is not required by law and we do not decide to
          hold a shareholder vote for business or other legal reasons, we will, pursuant to our amended and restated memorandum and articles of association, conduct the redemptions pursuant to the tender offer rules of the SEC, and file tender offer
          documents with the SEC prior to completing our partnering transaction. Our amended and restated memorandum and articles of association requires these tender offer documents to contain substantially the same financial and other information about
          our partnering transaction and the redemption rights as is required under the SEC’s proxy rules. If, however, a shareholder approval of the transaction is required by law, or we decide to obtain shareholder approval for business or other legal
          reasons, we will, like many special purpose acquisition companies, offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If we seek shareholder approval, we will
          complete our partnering transaction only if we receive an ordinary resolution under Cayman Islands law, which requires the affirmative vote of a majority of the shareholders who attend and vote at a general meeting of the company. However, the
          participation of our sponsor, officers, directors, advisors or their affiliates in privately-negotiated transactions, if any, could result in the approval of our partnering transaction even if a majority of our public shareholders vote, or
          indicate their intention to vote, against such partnering transaction. For purposes of seeking approval of the majority of our outstanding ordinary shares, non-votes will have no effect on the approval of our partnering transaction once a quorum
          is obtained. Our amended and restated memorandum and articles
          of association require that at least five days’ notice will be given of any general meeting.

       

      
        
          

      

      If we seek shareholder approval of our partnering transaction and we do not conduct redemptions in connection with our partnering transaction pursuant to the tender offer rules, our amended and
        restated memorandum and articles of association provides that a public shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of
        the Exchange Act), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the ordinary shares sold in our initial public offering, which we refer to as the “Excess Shares,” without our prior consent. However,
        we would not be restricting our shareholders’ ability to vote all of their shares (including Excess Shares) for or against our partnering transaction. Our shareholders’ inability to redeem the Excess Shares will reduce their influence over our
        ability to complete our partnering transaction, and such shareholders could suffer a material loss in their investment if they sell such Excess Shares on the open market. Additionally, such shareholders will not receive redemption distributions
        with respect to the Excess Shares if we complete our partnering transaction. And, as a result, such shareholders will continue to hold that number of shares exceeding 20% and, in order to dispose such shares would be required to sell their shares
        in open market transactions, potentially at a loss.

       

      If we seek shareholder approval in connection with our partnering
          transaction, our sponsor, officers and directors have agreed to vote any founder shares and performance shares they hold and any public shares purchased during or after our initial public offering (including in open market and privately-negotiated transactions) in favor of our partnering transaction.
          As a result, in addition to the founder shares and the performance shares, we would need 12,640,500, or 45%, of the 28,090,000 public shares sold in our initial public offering to be voted in favor of our partnering transaction in order to have
          our partnering transaction approved (assuming all outstanding shares are voted). Additionally, each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against the proposed transaction.

       

      Pursuant to our amended and restated memorandum and articles of association, if we have not completed our partnering transaction by October 6, 2023 (or such later date as approved by holders of a
        majority of the voting power of our outstanding ordinary shares that are voted at a meeting to extend such date, voting together as a single class), we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as
        reasonably possible but no more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in
        the trust account (net of permitted withdrawals and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as
        shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our
        board of directors, liquidate and dissolve, subject in each case to our obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. Our initial shareholders have entered into agreements with
        us, pursuant to which they have agreed to waive their rights to liquidating distributions from the trust account with respect to their founder shares if we fail to complete our partnering transaction by October 6, 2023. However, if our initial
        shareholders or management team acquire public shares in or after our initial public offering, they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete our partnering
        transaction within the prescribed time period.

       

      
        
          

      

      In the event of a liquidation, dissolution or winding up of the company after our partnering transaction, our shareholders are entitled to share ratably in all assets remaining available for
        distribution to them after payment of liabilities and after provision is made for each class of shares, if any, having preference over the ordinary shares. Our shareholders have no preemptive or other subscription rights. There are no sinking fund
        provisions applicable to the ordinary shares, except that we will provide our public shareholders with the opportunity to redeem their public shares for cash at a per share price equal to the aggregate amount then on deposit in the trust account,
        including interest earned on the funds held in the trust account (net of permitted withdrawals and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, upon the completion of our
        partnering transaction, subject to the limitations described herein.

       

      Founder Shares

       

      

      The founder shares are designated as Class F ordinary shares and, except as described below, are identical to the Class A ordinary shares included in the units sold in our initial public offering,
        and holders of founder shares have the same shareholder rights as public shareholders, except that (i) the founder shares are subject to certain transfer restrictions, as described in more detail below, (ii) our sponsor, officers and directors have
        entered into a letter agreement with us, pursuant to which they have agreed (A) to waive their redemption rights with respect to any founder shares and public shares they hold in connection with the completion of our partnering transaction, (B) to
        waive their redemption rights with respect to any founder shares and public shares they hold in connection with a shareholder vote to approve an amendment to our amended and restated memorandum and articles of association to modify the substance or
        timing of our obligation to redeem 100% of our public shares if we have not consummated our partnering transaction by October 6, 2023, or with respect to any other material provisions relating to shareholders’ rights or pre-partnering transaction
        activity and (C) to waive their rights to liquidating distributions from the trust account with respect to any founder shares they hold if we fail to complete our partnering transaction by October 6, 2023, although they will be entitled to
        liquidating distributions from the trust account with respect to any public shares they hold if we fail to complete our partnering transaction within such time period, (iii) the founder shares are automatically convertible into Class A ordinary
        shares concurrently with or immediately following the consummation of our partnering transaction on a one-for-one basis, subject to adjustment, as described herein and in our amended and restated memorandum and articles of association, and (iv)
        only holders of founder shares will have the right to appoint directors in any general meeting held prior to or in connection with the completion of our partnering transaction. If we submit our partnering transaction to our public shareholders for
        a vote, our initial shareholders have agreed to vote their founder shares, performance shares and any public shares purchased during or after our initial public offering in favor of our partnering transaction.

       

      
        
          

      

      The founder shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of our partnering transaction on a one-for-one basis, subject
        to adjustment, for share splits, share dividends, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that Class A additional ordinary shares or equity-linked securities are issued or
        deemed issued in connection with our partnering transaction, the number of Class A ordinary shares issuable upon conversion of all founder shares will equal, in the aggregate, on an as-converted basis, 5% of the total number of as-converted Class A
        ordinary shares outstanding after such conversion (including the forward purchase securities), including the total number of Class A ordinary shares issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or
        rights issued or deemed issued, by the Company in connection with or in relation to the consummation of our partnering transaction; provided that such conversion of founder shares into Class A ordinary
        shares will never occur on a less than one-for-one basis.

       

      The founder shares will be entitled to (together with the performance shares) a number of votes representing 20% of our outstanding ordinary shares prior to the completion of our partnering
        transaction.

       

      For so long as any founder shares remain outstanding, we may not, without the prior vote or written consent of the holders of a majority of the founder shares then outstanding, voting separately as
        a single class, amend, alter or repeal any provision of our memorandum and articles of association, whether by merger, consolidation or otherwise, if such amendment, alteration or repeal would alter or change the powers, preferences or relative,
        participating, optional or other or special rights of the founder shares. Any action required or permitted to be taken at any meeting of the holders of the founder shares may be taken without a meeting, without prior notice and without a vote, if a
        consent or consents in writing, setting forth the action so taken, shall be signed by the holders of the outstanding founder shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a
        meeting at which all founder shares were present and voted.

       

      Performance Shares

       

      

      One of our fundamental tenets is alignment of interests. Hence, we believe that it is important to align interests from an economic perspective in our partnering transaction. As part of the units
        design, we have created an incentive structure which rewards long term performance while also minimizing dilution. We believe that this structure is more in-line with our long term investment approach.

      

      

      
        
          

      

      On the last day of each fiscal year following the consummation of our partnering transaction (and, with respect to any year in which we have a change of control or in which we liquidate, dissolve
        or wind up, on the business day immediately prior to such event instead of on the last day of such fiscal year), 25,000 performance shares will automatically convert into Class A ordinary shares (“conversion shares”), as follows:

      

      

      
        	

              	•	
                If the price per Class A ordinary share has not exceeded $10.00 for 20 out of 30 consecutive trading days at any time following completion of our partnering transaction, the number of conversion shares for any fiscal year will be 2,500
                  Class A ordinary shares.

              

        

        

        	

              	•	
                If the price per Class A ordinary share exceeded $10.00 for 20 out of any 30 consecutive trading days at any time following completion of our partnering transaction, then the number of conversion shares for any fiscal year will be the
                  greater of:

              

        

        

        	

              	•	
                20% of the increase in the price of one Class A share, year-over-year but in respect of the increase above the relevant “price threshold” (as defined below), multiplied by the number of Class A ordinary shares outstanding at the close of our partnering transaction, excluding those ordinary shares received by our sponsor through the Class F ordinary shares, divided by the annual volume weighted average price of our Class A ordinary shares for such fiscal year (the “annual VWAP”) and

              

        

        

        	

              	•	
                2,500 Class A ordinary shares.

              

      

      

      

      	

            	•	
              The increase in the price of our Class A ordinary shares will be based on the annual VWAP for the relevant fiscal year, it being understood that with respect to the 10th fiscal year following our partnering transaction the conversion
                calculation for the remaining 25,000 performance shares, the calculation described in the immediately preceding bullet will be based on the greater of (i) the annual VWAP for such fiscal year and (ii) the VWAP of our Class A ordinary shares
                over the last 20 trading days for such fiscal year.

            

      

      

      	

            	•	
              For purposes of the foregoing calculations, the “price threshold” will initially equal $10.00 for the first fiscal year following completion of our partnering transaction and will thereafter be adjusted at
                the beginning of each subsequent fiscal year to be equal to the greater of (i) the annual VWAP for the immediately preceding fiscal year and (ii) the price threshold for the preceding fiscal year.

            

      

      

      	

            	•	
              For calculation purposes, the total number of Class A ordinary shares outstanding at the closing of our partnering transaction can be no smaller than 56,180,000 Class A ordinary shares and no greater than 112,360,000 Class A ordinary
                shares.

            

      

      

      	

            	•	
              The foregoing calculations will be based on our fiscal year, which may change as a result of our partnering transaction.

            

      

      

      
        
          

      

      For purpose of illustration of the number of Class A ordinary shares that would be issued upon conversion of the performance shares, assuming the total number of Class A ordinary shares outstanding
        at the close of our partnering transaction is 50,000,000 assuming the annual VWAP is $10.00 at the end of the first fiscal year following the completion of our partnering transaction and assuming that the price per Class A Ordinary share has not
        exceeded $10.00 for 20 out of any 30 consecutive trading days following completion of our partnering transaction, then 25,000 performance shares would convert into 2,500 Class A ordinary shares at the end of the first fiscal year.

      

      

      In contrast, assuming the annual VWAP is $15.00 at the end of the first fiscal year following the completion of our partnering transaction (as opposed to $10.00) and the price per Class A ordinary
        share has exceeded $10.00 for 20 out of any 30 consecutive trading days after our partnering transaction, the 25,000 performance shares at fiscal year-end would convert into 3,333,333 Class A ordinary shares. The appreciation in the annual VWAP is
        $15.00 less the initial price threshold of $10.00, or $5.00. The conversion amount is calculated as 20% of such appreciation, or $1.00, multiplied by 50,000,000, which results in $50,000,000. Such amount is then divided by the annual VWAP of
        $15.00, which yields 3,333,333 Class A ordinary shares. Thus, 25,000 performance shares would convert into 3,333,333 Class A ordinary shares at the end of the first fiscal year.

      

      

      Continuing with the example above, at the end of the second fiscal year following the completion of our partnering transaction, assuming the annual VWAP is $12.50, the 25,000 performance shares at
        year end would convert into only 2,500 Class A ordinary shares because the annual VWAP for the second fiscal year of $12.50 is less than the annual VWAP of $15.00 for the first fiscal year. If the annual VWAP at the end of the second fiscal year
        following the completion of our partnering transaction was instead $17.00, then the 25,000 performance shares would convert into 1,176,471 Class A ordinary shares. The appreciation in the annual VWAP would be $17.00 less $15.00, or $2.00. The
        conversion amount is calculated as 20% of such appreciation, or $0.40, multiplied by 50,000,000, which results in $20,000,000. Such amount is then divided by the annual VWAP of $17.00, which yields 1,176,471 ordinary shares.

      

      

      The conversion shares shall be deliverable 10 days following the end of each of the first 10 fiscal years following completion of our partnering transaction.

      

      

      The price threshold for a particular fiscal year will be reduced by the dividends per Class A ordinary share paid in such fiscal year.

      

      

      Upon a change of control occurring after our partnering transaction (but not in connection with our partnering transaction), holders of the performance shares shall receive cash, the amount of
        which is the greater of: (a) the value of approximately 5,618,000 Class A ordinary shares at the time of the announcement of the change of control or (b) $56,180,000. Such calculation shall decrease by 1/10 each year based on the number of days
        that have occurred during the fiscal year divided by 360.

       

      

      
        
          

      

      A change of control is the occurrence of any one of the following after our partnering transaction (but not in connection with our partnering transaction) if any of the following occurs: (a) a
        “person” or “group” within the meaning of Section 13(d) of the Exchange Act, other than us, our wholly owned subsidiaries and our and their respective employee benefit plans, (A) has become the direct or indirect “beneficial owner,” as defined in
        Rule 13d-3 under the Exchange Act, of ordinary shares representing more than 50% of the voting power of the Ordinary Shares and (B) has filed a Schedule TO or any schedule, form or report under the Exchange Act disclosing that an event described in
        clause (A) has occurred; provided, however, that a “person” or “group” shall not be deemed a beneficial owner of, or to own beneficially, any securities tendered pursuant to a tender or exchange offer made by or on behalf of such “person” or
        “group” or any of their affiliates until such tendered securities are accepted for purchase or exchange thereunder; (b) the consummation of (A) any recapitalization, reclassification or change of the ordinary shares (other than a change from no par
        value to par value, a change in par value or a change from par value to no par value, or changes resulting from a subdivision or combination) as a result of which all of the ordinary shares would be converted into, or exchanged for, stock, other
        securities, or other property or assets; (B) any share exchange, consolidation or merger of us pursuant to which all of the Class A ordinary shares will be converted into cash, securities or other property or assets (including any combination
        thereof); or (C) any sale, lease or other transfer in one transaction or a series of transactions of all or substantially all of our or our consolidated assets, taken as a whole, to any person or entity, other than one of our the wholly owned
        subsidiaries; provided, however, that a transaction described in clauses (A) or (B) in which the holders of all classes of our common equity immediately prior to such transaction own, directly or indirectly, more than 50% of all classes of the
        common equity of the continuing or surviving entity immediately after such transaction in substantially the same proportions as such ownership immediately prior to such transaction shall not be a change of control pursuant to this clause (b); (c)
        our shareholders approve any plan or proposal for our liquidation or dissolution (other than a liquidation or dissolution that will occur contemporaneously with a transaction described in clause (b)(B) above); or (d) our Class A ordinary shares
        ceases to be listed or quoted on any of The New York Stock Exchange, the Nasdaq Global Select Market or the Nasdaq Global Market (or any of their respective successors); provided, however, that a
        transaction or transactions described in clauses (a) or (b) above shall not constitute a change of control, if at least 90% of the consideration received or to be received by the holders of our ordinary shares, excluding cash payments for
        fractional shares and cash payments made in respect of dissenters’ appraisal rights, in connection with such transaction or transactions consists of ordinary shares that are listed or quoted on any of The New York Stock Exchange, the Nasdaq Global
        Select Market or the Nasdaq Global Market (or any of their respective successors) or will be so listed or quoted when issued or exchanged in connection with such transaction or transactions, and as a result of such transaction or transactions such
        consideration becomes the equity interests in which the performance shares convert into.

       

      For so long as any performance shares remain outstanding, including prior to our partnering transaction, in connection with our partnering transaction, or following our partnering
          transaction, we may not, without the prior vote or written consent of the holders of a majority of the performance shares then outstanding, voting separately as a single class, (A) amend, alter or repeal any provision our amended and restated
          memorandum and articles of association, whether by merger, consolidation or otherwise, if such amendment, alteration or repeal would alter or change the powers, preferences or relative, participating, optional or other or special rights of the
          Class B ordinary shares, (B) change our fiscal year, (C) increase the number of directors on the Board, (D) pay any dividends or effect any split on any of our share capital or make any distributions of cash, securities or any other property, (E)
          adopt any shareholder rights plan, (F) acquire any entity or business with assets at a purchase price greater than 10% or more of our total assets measured in accordance with generally accepted accounting principles in the United States or the
          accounting standards then used by us in the preparation of our financial statements, (G) issue any Class A ordinary shares in excess of 20% of our then outstanding Class A ordinary shares or that would otherwise require a shareholder vote
          pursuant to the rules of the stock exchange on which the Class A ordinary shares are then listed or (H) make a rights offering to all or substantially all of the holders of Class B ordinary shares or issue additional Class B ordinary shares. Any
          action required or permitted to be taken at any meeting of the holders of performance shares may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be
          signed by the holders of the outstanding Class B ordinary shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all performance shares were present and voted.

       

      
        
          

      

      The performance shares will be entitled to (together with the founder shares) a number of votes representing 20% of our outstanding ordinary shares prior to the completion of our partnering
        transaction.

       

      In addition, our board of directors (in consultation with our sponsor) may make a one-time election following consummation of our initial public offering and prior to completion of our partnering
        transaction to require our sponsor to forfeit all of the performance shares simultaneously with the issuance of a share dividend to all holders of founder shares such that after giving effect to such transactions no performance shares remain
        outstanding and the number of founder shares outstanding is equal to 20% of the then outstanding ordinary shares on an as-converted basis. We refer to this election as the “promote conversion,” and this election may only be made if our board of
        directors determines that such election is reasonably necessary or beneficial to facilitate the execution of our partnering transaction.

       

      Register of Members

       

      

      Under Cayman Islands law, we must keep a register of members and there will be entered therein:

      

      

      	

            	•	
              the names and addresses of the members, a statement of the shares held by each member, and of the amount paid or agreed to be considered as paid, on the shares of each member and the voting rights of shares
                of each member;

            

      

      

      	

            	•	
              the date on which the name of any person was entered on the register as a member; and

            

      

      

      	

            	•	
              the date on which any person ceased to be a member.

            

      

      

      
        
          

      

      Under Cayman Islands law, the register of members of our company is prima facie evidence of the matters set out therein (i.e. the register of members will raise a presumption of fact on the matters
        referred to above unless rebutted) and a member registered in the register of members will be deemed as a matter of Cayman Islands law to have legal title to the shares as set against its name in the register of members. Upon the closing of our
        initial public offering, the register of members was immediately updated to reflect the issue of shares by us. Once our register of members has been updated, the shareholders recorded in the register of members will be deemed to have legal title to
        the shares set against their name. However, there are certain limited circumstances where an application may be made to a Cayman Islands court for a determination on whether the register of members reflects the correct legal position. Further, the
        Cayman Islands court has the power to order that the register of members maintained by a company should be rectified where it considers that the register of members does not reflect the correct legal position. If an application for an order for
        rectification of the register of members were made in respect of our ordinary shares, then the validity of such shares may be subject to re-examination by a Cayman Islands court.

      

      

      Preference Shares

       

      

      Our amended and restated memorandum and articles of association authorizes 1,000,000 preference shares and provides that preference shares may be issued from time to time in one or more series. Our
        board of directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the
        shares of each series. Our board of directors is able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the ordinary shares and
        could have anti-takeover effects. The ability of our board of directors to issue preference shares without shareholder approval could have the effect of delaying, deferring or preventing a change of control of us or the removal of existing
        management. We have no preference shares issued and outstanding at the date hereof. Although we do not currently intend to issue any preference shares, we cannot assure you that we will not do so in the future.

      

      

      Warrants

      

      

      Public Shareholders’ Warrants

      

      

      Each whole warrant entitles the registered holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment, as discussed below, at any time commencing 30 days
        after the completion of our partnering transaction, provided, in each case, that we have an effective registration statement under the Securities Act covering the Class A ordinary shares issuable upon exercise of the warrants and a current
        prospectus relating to them is available (or we permit holders to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement) and such shares are registered, qualified or exempt from registration under
        the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of Class A ordinary shares. This means only a whole warrant may be
        exercised at a given time by a warrant holder. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Accordingly, unless you purchase at least four units, you will not be able to receive or trade a
        whole warrant. The warrants will expire five years after the completion of our partnering transaction, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

      

      

      
        
          

      

      We are not obligated to deliver any Class A ordinary shares pursuant to the exercise of a warrant and have no obligation to settle such warrant exercise unless a registration statement under the
        Securities Act with respect to the Class A ordinary shares underlying the warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration. No warrant is
        exercisable and we are not obligated to issue a Class A ordinary share upon exercise of a warrant unless the Class A ordinary share issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws
        of the state of residence of the registered holder of the warrants.

      

      

      In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and
        such warrant may have no value and expire worthless. In no event are we required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a unit containing such warrant
        will have paid the full purchase price for the unit solely for the Class A ordinary share underlying such unit.

      

      

      We have agreed that as soon as practicable, but in no event later than fifteen (15) business days after the closing of our partnering transaction, we will use our commercially reasonable efforts to
        file with the SEC a post-effective amendment to the registration statement for the registration, under the Securities Act, of the Class A ordinary shares issuable upon exercise of the warrants. We will use our commercially reasonable efforts to
        cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If a
        registration statement covering the Class A ordinary shares issuable upon exercise of the warrants is not effective by the sixtieth (60th) business day after the closing of our partnering transaction, warrant holders may, until such time as there
        is an effective registration statement and during any period when we will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another
        exemption. Notwithstanding the above, if our Class A ordinary shares are at the time of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of a “covered security” under Section 18(b)(1) of
        the Securities Act, we may, at our option, require holders of public warrants who exercise their warrants to do so on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act and, in the event we so elect, we will not be required
        to file or maintain in effect a registration statement, and in the event we do not so elect, we will use our commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not
        available.

      

      

      Redemption of Warrants for Cash When the Price per Class A Ordinary Share Equals or Exceeds $18.00

      

      

      Once the warrants become exercisable, we may call the warrants for redemption for cash:

      

      

      	

            	•	
              in whole and not in part;

            

      

      

      
        
          

      

      	

            	•	
              at a price of $0.01 per warrant;

            

      

      

      	

            	•	
              upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and

            

      

      

      	

            	•	
              if, and only if, the closing price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for
                any 20 trading days within a 30-trading day period ending three business days before we send to the notice of redemption to the warrant holders.

            

      

      

      If and when the warrants become redeemable by us for cash, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale under all applicable
        state securities laws.

      

      

      We have established the last of the redemption criteria discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the warrant exercise price. If
        the foregoing conditions are satisfied and we issue a notice of redemption of the warrants, each warrant holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of the Class A ordinary
        shares may fall below the $18.00 redemption trigger price (as adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 warrant exercise price after the redemption notice is issued.

      

      

      Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $10.00

      

      

      Once the warrants become exercisable, we may redeem the outstanding warrants:

      

      

      	

            	•	
              in whole and not in part;

            

      

      

      	

            	•	
              at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption; provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that
                number of shares determined by reference to the table below, based on the redemption date and the “fair market value” of our Class A ordinary shares (as defined below);

            

      

      

      	

            	•	
              if, and only if, the Reference Value (as defined above under “Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00”) equals or exceeds $10.00 per share (as adjusted for
                share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like); and

            

      

      

      	

            	•	
              if the Reference Value is less than $18.00 per share (as adjusted for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) the private placement warrants must also be
                concurrently called for redemption on the same terms as the outstanding public warrants, as described above.

            

      

      

      
        
          

      

      The numbers in the table below represent the number of Class A ordinary shares that a warrant holder will receive upon exercise in connection with a redemption by us pursuant to this redemption
        feature, based on the “fair market value” of our Class A ordinary shares on the corresponding redemption date (assuming holders elect to exercise their warrants and such warrants are not redeemed for $0.10 per warrant), determined based on
        volume-weighted average price of our Class A ordinary shares as reported during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants, and the number of months that the corresponding
        redemption date precedes the expiration date of the warrants, each as set forth in the table below. We will provide our warrant holders with the final fair market value no later than one business day after the 10-trading day period described above
        ends.

      

      

      Pursuant to the warrant agreement, references above to Class A ordinary shares shall include a security other than Class A ordinary shares into which the Class A ordinary shares have been converted
        or exchanged for in the event we are not the surviving company in our initial business combination.

      

      

      The numbers in the table below will not be adjusted when determining the number of Class A ordinary shares to be issued upon exercise of the warrants if we are not the surviving entity following
        our initial business combination.

      

      

      The share prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of a warrant or the exercise price of the
        warrant is adjusted as set forth under the heading “—Adjustment to Exercise Price” below. If the number of shares issuable upon exercise of a warrant is adjusted, the adjusted share prices in the column headings will equal the share prices
        immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the exercise price of the warrant after such adjustment and the denominator of which is the price of the warrant immediately prior to such adjustment. In such
        an event, the number of shares in the table below shall be adjusted by multiplying such share amounts by a fraction, the numerator of which is the number of shares deliverable upon exercise of a warrant immediately prior to such adjustment and the
        denominator of which is the number of shares deliverable upon exercise of a warrant as so adjusted. If the exercise price of the warrant is adjusted as a result of raising capital in connection with the initial business combination, the adjusted
        share prices in the column headings will by multiplied by a fraction, the numerator of which is the higher of the Market Value and the Newly Issued Price as set forth under the heading “—Adjustment to Exercise Price” and the denominator of which is
        $10.00.

       

      

      
        
          

      

      	 	 	
              Fair Market Value of Class A Ordinary Shares

            	 	 	 	 
	
              Redemption Date (period to

              expiration of warrants)

            	 	
              

              

            	
              $10.00

            	 	 	

            	
              $11.00

            	 	 	
              

              

            	
              $12.00

            	 	 	
              

              

            	
              $13.00

            	 	 	

            	
              $14.00

            	 	 	

            	
              $15.00

            	 	 	

            	
              $16.00

            	 	 	
              

              

            	
              $17.00

            	 	 	

            	
              $18.00

            	 
	
              60 months

            	 	 	
              0.261

            	 	 	 	
              0.281

            	 	 	 	
              0.297

            	 	 	 	
              0.311

            	 	 	 	
              0.324

            	 	 	 	
              0.337

            	 	 	 	
              0.348

            	 	 	 	
              0.358

            	 	 	 	
              0.361

            	 
	
              57 months

            	 	 	
              0.257

            	 	 	 	
              0.277

            	 	 	 	
              0.294

            	 	 	 	
              0.310

            	 	 	 	
              0.324

            	 	 	 	
              0.337

            	 	 	 	
              0.348

            	 	 	 	
              0.358

            	 	 	 	
              0.361

            	 
	
              54 months

            	 	 	
              0.252

            	 	 	 	
              0.272

            	 	 	 	
              0.291

            	 	 	 	
              0.307

            	 	 	 	
              0.322

            	 	 	 	
              0.335

            	 	 	 	
              0.347

            	 	 	 	
              0.357

            	 	 	 	
              0.361

            	 
	
              51 months

            	 	 	
              0.246

            	 	 	 	
              0.268

            	 	 	 	
              0.287

            	 	 	 	
              0.304

            	 	 	 	
              0.320

            	 	 	 	
              0.333

            	 	 	 	
              0.346

            	 	 	 	
              0.357

            	 	 	 	
              0.361

            	 
	
              48 months

            	 	 	
              0.241

            	 	 	 	
              0.263

            	 	 	 	
              0.283

            	 	 	 	
              0.301

            	 	 	 	
              0.317

            	 	 	 	
              0.332

            	 	 	 	
              0.344

            	 	 	 	
              0.356

            	 	 	 	
              0.361

            	 
	
              45 months

            	 	 	
              0.235

            	 	 	 	
              0.258

            	 	 	 	
              0.279

            	 	 	 	
              0.298

            	 	 	 	
              0.315

            	 	 	 	
              0.330

            	 	 	 	
              0.343

            	 	 	 	
              0.356

            	 	 	 	
              0.361

            	 
	
              42 months

            	 	 	
              0.228

            	 	 	 	
              0.252

            	 	 	 	
              0.274

            	 	 	 	
              0.294

            	 	 	 	
              0.312

            	 	 	 	
              0.328

            	 	 	 	
              0.342

            	 	 	 	
              0.355

            	 	 	 	
              0.361

            	 
	
              39 months

            	 	 	
              0.221

            	 	 	 	
              0.246

            	 	 	 	
              0.269

            	 	 	 	
              0.290

            	 	 	 	
              0.309

            	 	 	 	
              0.325

            	 	 	 	
              0.340

            	 	 	 	
              0.354

            	 	 	 	
              0.361

            	 
	
              36 months

            	 	 	
              0.213

            	 	 	 	
              0.239

            	 	 	 	
              0.263

            	 	 	 	
              0.285

            	 	 	 	
              0.305

            	 	 	 	
              0.323

            	 	 	 	
              0.339

            	 	 	 	
              0.353

            	 	 	 	
              0.361

            	 
	
              33 months

            	 	 	
              0.205

            	 	 	 	
              0.232

            	 	 	 	
              0.257

            	 	 	 	
              0.280

            	 	 	 	
              0.301

            	 	 	 	
              0.320

            	 	 	 	
              0.337

            	 	 	 	
              0.352

            	 	 	 	
              0.361

            	 
	
              30 months

            	 	 	
              0.196

            	 	 	 	
              0.224

            	 	 	 	
              0.250

            	 	 	 	
              0.274

            	 	 	 	
              0.297

            	 	 	 	
              0.316

            	 	 	 	
              0.335

            	 	 	 	
              0.351

            	 	 	 	
              0.361

            	 
	
              27 months

            	 	 	
              0.185

            	 	 	 	
              0.214

            	 	 	 	
              0.242

            	 	 	 	
              0.268

            	 	 	 	
              0.291

            	 	 	 	
              0.313

            	 	 	 	
              0.332

            	 	 	 	
              0.350

            	 	 	 	
              0.361

            	 
	
              24 months

            	 	 	
              0.173

            	 	 	 	
              0.204

            	 	 	 	
              0.233

            	 	 	 	
              0.260

            	 	 	 	
              0.285

            	 	 	 	
              0.308

            	 	 	 	
              0.329

            	 	 	 	
              0.348

            	 	 	 	
              0.361

            	 
	
              21 months

            	 	 	
              0.161

            	 	 	 	
              0.193

            	 	 	 	
              0.223

            	 	 	 	
              0.252

            	 	 	 	
              0.279

            	 	 	 	
              0.304

            	 	 	 	
              0.326

            	 	 	 	
              0.347

            	 	 	 	
              0.361

            	 
	
              18 months

            	 	 	
              0.146

            	 	 	 	
              0.179

            	 	 	 	
              0.211

            	 	 	 	
              0.242

            	 	 	 	
              0.271

            	 	 	 	
              0.298

            	 	 	 	
              0.322

            	 	 	 	
              0.345

            	 	 	 	
              0.361

            	 
	
              15 months

            	 	 	
              0.130

            	 	 	 	
              0.164

            	 	 	 	
              0.197

            	 	 	 	
              0.230

            	 	 	 	
              0.262

            	 	 	 	
              0.291

            	 	 	 	
              0.317

            	 	 	 	
              0.342

            	 	 	 	
              0.361

            	 
	
              12 months

            	 	 	
              0.111

            	 	 	 	
              0.146

            	 	 	 	
              0.181

            	 	 	 	
              0.216

            	 	 	 	
              0.250

            	 	 	 	
              0.282

            	 	 	 	
              0.312

            	 	 	 	
              0.339

            	 	 	 	
              0.361

            	 
	
              9 months

            	 	 	
              0.090

            	 	 	 	
              0.125

            	 	 	 	
              0.162

            	 	 	 	
              0.199

            	 	 	 	
              0.237

            	 	 	 	
              0.272

            	 	 	 	
              0.305

            	 	 	 	
              0.336

            	 	 	 	
              0.361

            	 
	
              6 months

            	 	 	
              0.065

            	 	 	 	
              0.099

            	 	 	 	
              0.137

            	 	 	 	
              0.178

            	 	 	 	
              0.219

            	 	 	 	
              0.259

            	 	 	 	
              0.296

            	 	 	 	
              0.331

            	 	 	 	
              0.361

            	 
	
              3 months

            	 	 	
              0.034

            	 	 	 	
              0.065

            	 	 	 	
              0.104

            	 	 	 	
              0.150

            	 	 	 	
              0.197

            	 	 	 	
              0.243

            	 	 	 	
              0.286

            	 	 	 	
              0.326

            	 	 	 	
              0.361

            	 
	
              0 months

            	 	 	
              -

            	 	 	 	
              -

            	 	 	 	
              0.042

            	 	 	 	
              0.115

            	 	 	 	
              0.179

            	 	 	 	
              0.233

            	 	 	 	
              0.281

            	 	 	 	
              0.323

            	 	 	 	
              0.361

            	 

      

      

      The exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between two values in the table or the redemption date is between
        two redemption dates in the table, the number of Class A ordinary shares to be issued for each warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the higher and lower fair market values
        and the earlier and later redemption dates, as applicable, based on a 365 or 366-day year, as applicable. For example, if the volume-weighted average price of our Class A ordinary shares as reported during the 10 trading days immediately following
        the date on which the notice of redemption is sent to the holders of the warrants is $11.00 per share, and at such time there are 57 months until the expiration of the warrants, holders may choose to, in connection with this redemption feature,
        exercise their warrants for 0.277 Class A ordinary shares for each whole warrant.

      

      

      For an example where the exact fair market value and redemption date are not as set forth in the table above, if the volume-weighted average price of our Class A ordinary shares as reported during
        the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the warrants is $13.50 per share, and at such time there are 38 months until the expiration of the warrants, holders may choose to, in
        connection with this redemption feature, exercise their warrants for 0.298 Class A ordinary shares for each whole warrant. In no event will the warrants be exercisable in connection with this redemption feature for more than 0.361 Class A ordinary
        shares per warrant (subject to adjustment).

      

      

      
        
          

      

      This redemption feature is structured to allow for all of the outstanding warrants to be redeemed when the Class A ordinary shares are trading at or above $10.00 per share, which may be at a time
        when the trading price of our Class A ordinary shares is below the exercise price of the warrants. We have established this redemption feature to provide us with the flexibility to redeem the warrants without the warrants having to reach the $18.00
        per share threshold set forth above under “—Redemption of Warrants When the Price per Class A Ordinary Share Equals or Exceeds $18.00.” Holders choosing to exercise their warrants in connection with a redemption pursuant to this feature will, in
        effect, receive a number of shares for their warrants based on an option pricing model with a fixed volatility input as of June 30, 2021. This redemption right provides us with an additional mechanism by which to redeem all of the outstanding
        warrants, and therefore have certainty as to our capital structure as the warrants would no longer be outstanding and would have been exercised or redeemed. We will be required to pay the applicable redemption price to warrant holders if we choose
        to exercise this redemption right and it will allow us to quickly proceed with a redemption of the warrants if we determine it is in our best interest to do so. As such, we would redeem the warrants in this manner when we believe it is in our best
        interest to update our capital structure to remove the warrants and pay the redemption price to the warrant holders. As stated above, we can redeem the warrants when the Class A ordinary shares are trading at a price starting at $10.00, which is
        below the exercise price of $11.50, because it will provide certainty with respect to our capital structure and cash position while providing warrant holders with the opportunity to exercise their warrants on a cashless basis for the applicable
        number of shares. If we choose to redeem the warrants when the Class A ordinary shares are trading at a price below the exercise price of the warrants, this could result in the warrant holders receiving fewer Class A ordinary shares than they would
        have received if they had chosen to wait to exercise their warrants for Class A ordinary shares if and when such Class A ordinary shares were trading at a price higher than the exercise price of $11.50.

      

      

      No fractional Class A ordinary shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, we will round down to the nearest
        whole number of the number of Class A ordinary shares to be issued to the holder. If, at the time of redemption, the warrants are exercisable for a security other than the Class A ordinary shares pursuant to the warrant agreement (for instance, if
        we are not the surviving company in our initial business combination), the warrants may be exercised for such security. At such time as the warrants become exercisable for a security other than the Class A ordinary shares, the Company (or surviving
        company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the warrants.

      

      

      Redemption Procedures. A holder of a warrant may notify us in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect
          to such exercise, such person (together with such person’s affiliates), to the warrant agent’s actual knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of the Class A ordinary shares outstanding immediately
          after giving effect to such exercise.

       

         

      
        
          

      

      Adjustment to Exercise Price. If the number of outstanding Class A ordinary shares is increased by a share capitalization payable in Class A ordinary shares, or by a split-up of ordinary shares or other similar event,
          then, on the effective date of such share capitalization, split-up or similar event, the number of Class A ordinary shares issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding ordinary shares. A
          rights offering to all or substantially holders of Class A ordinary shares entitling holders to purchase Class A ordinary shares at a price less than the fair market value will be deemed a share capitalization of a number of Class A ordinary
          shares equal to the product of (i) the number of Class A ordinary shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Class A
          ordinary shares) and (ii) one minus the quotient of (x) the price per Class A ordinary share paid in such rights offering and (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into or
          exercisable for Class A ordinary shares, in determining the price payable for Class A ordinary shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or
          conversion and (ii) fair market value means the VWAP of Class A ordinary shares as reported during the ten (10) trading day period ending on the trading day prior to the first date on which the Class A ordinary shares trades on the applicable
          exchange or in the applicable market, regular way, without the right to receive such rights.

      

      

       In addition, if we, at any time while the warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to all or substantially all holders of
        Class A ordinary shares on account of such Class A ordinary shares (or other securities into which the warrants are convertible), other than (a) as described above, (b) annual cash dividends in excess of $1.25 per share, (c) to satisfy the
        redemption rights of the holders of Class A ordinary shares in connection with our proposed partnering transaction or certain amendments to our memorandum and articles of association, including an extension of the time period in which we must
        complete our partnering transaction, or (d) in connection with the redemption of our public shares upon our failure to complete our partnering transaction, then the warrant exercise price will be decreased, effective immediately after the effective
        date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Class A ordinary share in respect of such event.

      

      

      If the number of outstanding Class A ordinary shares is decreased by a consolidation, combination, reverse share split or reclassification of Class A ordinary shares or other similar event, then,
        on the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of Class A ordinary shares issuable on exercise of each warrant will be decreased in proportion to such decrease in
        outstanding ordinary Class A share.

      

      

      Whenever the number of Class A ordinary shares purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted by multiplying the warrant
        exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number of Class A ordinary shares purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the denominator
        of which will be the number of Class A ordinary shares so purchasable immediately thereafter.

      

      

      In addition, if (x) we issue additional Class A ordinary shares or equity-linked securities, excluding the forward purchase shares, for capital raising purposes in connection with the closing of
        our partnering transaction, at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any
        such issuance to our initial shareholders or their affiliates, without taking into account any founder shares held by our initial shareholders or such affiliates, as applicable, prior to such issuance), (the “Newly Issued Price”) (y) the aggregate
        gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of our partnering transaction on the date of the consummation of our partnering transaction (net of
        redemptions), and (z) the volume weighted average trading price of our Class A ordinary shares during the 20 trading day period starting on the trading day after the day on which we consummate our partnering transaction (such price, the “Market
        Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 110% of the higher of the Market Value and the Newly Issued Price, and the $18.00 per share redemption trigger price
        described below under “Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180% of the higher of the Market Value and the Newly Issued Price.

      

      

      
        
          

      

      In case of any reclassification or reorganization of the outstanding Class A ordinary shares (other than those described above or that solely affects the par value of such Class A ordinary shares),
        or in the case of any merger or consolidation of us with or into another corporation (other than a consolidation or merger in which we are the continuing corporation and that does not result in any reclassification or reorganization of our
        outstanding Class A ordinary shares), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of us as an entirety or substantially as an entirety in connection with which we are dissolved, the
        holders of the warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of the Class A ordinary shares immediately theretofore purchasable and receivable
        upon the exercise of the rights represented thereby, the kind and amount of Class A ordinary shares or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a
        dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised their warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of
        Class A ordinary shares in such a transaction is payable in the form of ordinary shares in the successor entity that is listed for trading on a national securities exchange or is quoted in an established over-the-counter market, or is to be so
        listed for trading or quoted immediately following such event, and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure of such transaction, the warrant exercise price will be reduced
        as specified in the warrant agreement based on the Black-Scholes Warrant Value (as defined in the warrant agreement) of the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the warrants when an
        extraordinary transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise do not receive the full potential value of the warrants.

      

      

      Private Placement Warrants

       

      

      The private placement warrants (including the Class A ordinary shares issuable upon exercise of the private placement warrants) will not be transferable, assignable or salable until 30 days after
        the completion of our partnering transaction (except, among other limited exceptions, to our officers and directors and other persons or entities affiliated with the initial purchasers of the private placement warrants) and they will not be
        redeemable by us for cash so long as they are held by the initial shareholders or their permitted transferees. The initial purchasers, or their permitted transferees, have the option to exercise the private placement warrants on a cashless basis.
        Except as described in this section, the private placement warrants have terms and provisions that are identical to those of the warrants being sold as part of the units sold in our initial public offering. If the private placement warrants are
        held by holders other than the initial purchasers or their permitted transferees, the private placement warrants will be redeemable by us and exercisable by the holders on the same basis as the warrants included in the units being sold in our
        initial public offering.

      

      

      
        
          

      

      If holders of the private placement warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering each warrant for that number of Class A ordinary shares
        equal to the lesser of (A) the quotient obtained by dividing (x) the product of the number of Class A ordinary shares underlying the warrants, multiplied by the excess of the “fair market value” of our Class A ordinary shares (defined below) over
        the exercise price of the warrants by (y) the fair market value and (B) 0.361. The “fair market value” will mean the average closing price of the Class A ordinary shares for the 10 trading days ending on the third trading day prior to the date on
        which the notice of warrant exercise is sent to the warrant agent. The reason that we have agreed that these warrants will be exercisable on a cashless basis so long as they are held by the initial purchasers or their permitted transferees is
        because it is not known at this time whether they will be affiliated with us following our partnering transaction. If they remain affiliated with us, their ability to sell our securities in the open market will be significantly limited. We expect
        to have policies in place that prohibit insiders from selling our securities except during specific periods of time. Even during such periods of time when insiders will be permitted to sell our securities, an insider cannot trade in our securities
        if he or she is in possession of material non-public information. Accordingly, unlike public shareholders who could exercise their warrants and sell the Class A ordinary shares received upon such exercise freely in the open market in order to
        recoup the cost of such exercise, the insiders could be significantly restricted from selling such securities. As a result, we believe that allowing the holders to exercise such warrants on a cashless basis is appropriate.

      

      

      In order to finance transaction costs in connection with our intended partnering transaction, our sponsor or an affiliate of our sponsor or certain of our officers and directors may, but are not
        obligated to, loan us funds as may be required. Up to $1,500,000 of such loans may be convertible into private placement warrants of the post-partnering transaction entity at a price of $1.50 per private placement warrants at the option of the
        lender (which units will immediately split into Class A ordinary shares and warrants). Such warrants would be identical to the private placement warrants.

      

      

      Our initial shareholders have agreed not to transfer, assign or sell any of the private placement warrants (including the Class A ordinary shares issuable upon exercise of any of these warrants)
        until the date that is 30 days after the date we complete our partnering transaction, except that, among other limited exceptions, transfers can be made to our officers and directors and other persons or entities affiliated with the sponsor.

      

      

      Dividends

       

      

      We have not paid any cash dividends on our ordinary shares to date and do not intend to pay cash dividends prior to the completion of our partnering transaction. The payment of cash dividends in
        the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition subsequent to completion of our partnering transaction. The payment of any cash dividends subsequent to our partnering
        transaction will be within the discretion of our board of directors at such time. If we incur any indebtedness, our ability to declare dividends may be limited by restrictive covenants we may agree to in connection therewith.

       

         

      
        
          

      

      Our Transfer Agent and Warrant Agent

       

      

      The transfer agent for our ordinary shares and warrant agent for our warrants is Continental Stock Transfer & Trust Company. We have agreed to indemnify Continental Stock Transfer & Trust
        Company in its roles as transfer agent and warrant agent, its agents and each of its shareholders, directors, officers and employees against all claims and losses that may arise out of acts performed or omitted for its activities in that capacity,
        except for any liability due to any gross negligence or intentional misconduct of the indemnified person or entity. Continental Stock Transfer & Trust Company has agreed that it has no right of set-off or any right, title, interest or claim of
        any kind to, or to any monies in, the trust account, and has irrevocably waived any right, title, interest or claim of any kind to, or to any monies in, the trust account that it may have now or in the future. Accordingly, any indemnification
        provided will only be able to be satisfied, or a claim will only be able to be pursued, solely against us and our assets outside the trust account and not against the any monies in the trust account or interest earned thereon.

      

      

      Certain Differences in Corporate Law

       

      

      Cayman Islands companies are governed by the Companies Act. The Companies Act is modeled on English Law but does not follow recent English Law statutory enactments, and differs from laws applicable
        to United States corporations and their shareholders. Set forth below is a summary of the material differences between the provisions of the Companies Act applicable to us and the laws applicable to companies incorporated in the United States and
        their shareholders.

      

      

      Mergers and Similar Arrangements. In certain circumstances, the Companies Act allows for mergers or consolidations between two Cayman Islands companies, or between a Cayman Islands exempted company and a company
          incorporated in another jurisdiction (provided that is facilitated by the laws of that other jurisdiction).

      

      

      Where the merger or consolidation is between two Cayman Islands companies, the directors of each company must approve a written plan of merger or consolidation containing certain prescribed
        information. That plan or merger or consolidation must then be authorized by either (a) a special resolution (usually a majority of 662/3% in value of the voting
        shares voted at a general meeting) of the shareholders of each company; or (b) such other authorization, if any, as may be specified in such constituent company’s articles of association. No shareholder resolution is required for a merger between a
        parent company (i.e., a company that owns at least 90% of the issued shares of each class in a subsidiary company) and its subsidiary company. The consent of each holder of a fixed or floating security interest of a constituent company must be
        obtained, unless the court waives such requirement. If the Cayman Islands Registrar of Companies is satisfied that the requirements of the Companies Act (which includes certain other formalities) have been complied with, the Registrar of Companies
        will register the plan of merger or consolidation.

      

      

      
        
          

      

      Where the merger or consolidation involves a foreign company, the procedure is similar, save that with respect to the foreign company, the directors of the Cayman Islands exempted company are
        required to make a declaration to the effect that, having made due enquiry, they are of the opinion that the requirements set out below have been met: (i) that the merger or consolidation is permitted or not prohibited by the constitutional
        documents of the foreign company and by the laws of the jurisdiction in which the foreign company is incorporated, and that those laws and any requirements of those constitutional documents have been or will be complied with; (ii) that no petition
        or other similar proceeding has been filed and remains outstanding or order made or resolution adopted to wind up or liquidate the foreign company in any jurisdictions; (iii) that no receiver, trustee, administrator or other similar person has been
        appointed in any jurisdiction and is acting in respect of the foreign company, its affairs or its property or any part thereof; (iv) that no scheme, order, compromise or other similar arrangement has been entered into or made in any jurisdiction
        whereby the rights of creditors of the foreign company are and continue to be suspended or restricted.

      

      

      Where the surviving company is the Cayman Islands exempted company, the directors of the Cayman Islands exempted company are further required to make a declaration to the effect that, having made
        due enquiry, they are of the opinion that the requirements set out below have been met: (i) that the foreign company is able to pay its debts as they fall due and that the merger or consolidated is bona fide and not intended to defraud unsecured
        creditors of the foreign company; (ii) that in respect of the transfer of any security interest granted by the foreign company to the surviving or consolidated company (a) consent or approval to the transfer has been obtained, released or waived;
        (b) the transfer is permitted by and has been approved in accordance with the constitutional documents of the foreign company; and (c) the laws of the jurisdiction of the foreign company with respect to the transfer have been or will be complied
        with; (iii) that the foreign company will, upon the merger or consolidation becoming effective, cease to be incorporated, registered or exist under the laws of the relevant foreign jurisdiction; and (iv) that there is no other reason why it would
        be against the public interest to permit the merger or consolidation.

      

      

      Where the above procedures are adopted, the Companies Act provides for a right of dissenting shareholders to be paid a payment of the fair value of his shares upon their dissenting to the merger or
        consolidation if they follow a prescribed procedure. In essence, that procedure is as follows (a) the shareholder must give his written objection to the merger or consolidation to the constituent company before the vote on the merger or
        consolidation, including a statement that the shareholder proposes to demand payment for his shares if the merger or consolidation is authorized by the vote; (b) within 20 days following the date on which the merger or consolidation is approved by
        the shareholders, the constituent company must give written notice to each shareholder who made a written objection; (c) a shareholder must within 20 days following receipt of such notice from the constituent company, give the constituent company a
        written notice of his intention to dissent including, among other details, a demand for payment of the fair value of his shares; (d) within seven days following the date of the expiration of the period set out in paragraph (b) above or seven days
        following the date on which the plan of merger or consolidation is filed, whichever is later, the constituent company, the surviving company or the consolidated company must make a written offer to each dissenting shareholder to purchase his shares
        at a price that the company determines is the fair value and if the company and the shareholder agree the price within 30 days following the date on which the offer was made, the company must pay the shareholder such amount; and (e) if the company
        and the shareholder fail to agree a price within such 30 day period, within 20 days following the date on which such 30 day period expires, the company (and any dissenting shareholder) must file a petition with the Cayman Islands Grand Court to
        determine the fair value and such petition must be accompanied by a list of the names and addresses of the dissenting shareholders with whom agreements as to the fair value of their shares have not been reached by the company. At the hearing of
        that petition, the court has the power to determine the fair value of the shares together with a fair rate of interest, if any, to be paid by the company upon the amount determined to be the fair value. Any dissenting shareholder whose name appears
        on the list filed by the company may participate fully in all proceedings until the determination of fair value is reached. These rights of a dissenting shareholder are not available in certain circumstances, for example, to dissenters holding
        shares of any class in respect of which an open market exists on a recognized stock exchange or recognized interdealer quotation system at the relevant date or where the consideration for such shares to be contributed are shares of any company
        listed on a national securities exchange or shares of the surviving or consolidated company.

      

      

      
        
          

      

      Moreover, Cayman Islands law has separate statutory provisions that facilitate the reconstruction or amalgamation of companies in certain circumstances, schemes of arrangement will generally be
        more suited for complex mergers or other transactions involving widely held companies, commonly referred to in the Cayman Islands as a “scheme of arrangement” which may be tantamount to a merger. In the event that a merger was sought pursuant to a
        scheme of arrangement (the procedures for which are more rigorous and take longer to complete than the procedures typically required to consummate a merger in the United States), the arrangement in question must be approved by a majority in number
        of each class of shareholders and creditors with whom the arrangement is to be made and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in
        person or by proxy at a meeting, or meeting summoned for that purpose. The convening of the meetings and subsequently the terms of the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder would
        have the right to express to the court the view that the transaction should not be approved, the court can be expected to approve the arrangement if it satisfies itself that:

      

      

      	

            	•	
              we are not proposing to act illegally or beyond the scope of our corporate authority and the statutory provisions as to majority vote have been complied with;

            

      

      

      	

            	•	
              the shareholders have been fairly represented at the meeting in question;

            

      

      

      	

            	•	
              the arrangement is such as a businessman would reasonably approve; and

            

      

      

      	

            	•	
              the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Act or that would amount to a “fraud on the minority.”

            

      

      

      
        
          

      

      If a scheme of arrangement or takeover offer (as described below) is approved, any dissenting shareholder would have no rights comparable to appraisal rights (providing rights to receive payment in
        cash for the judicially determined value of the shares), which would otherwise ordinarily be available to dissenting shareholders of United States corporations.

      

      

      Squeeze-out Provisions. When a takeover offer is made and accepted by holders of 90% of the shares to whom the offer relates is made within four months, the offeror may, within a two-month period, require the holders of the
          remaining shares to transfer such shares on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed unless there is evidence of fraud, bad faith, collusion or inequitable treatment
          of the shareholders.

       

        

      Further, transactions similar to a merger, reconstruction and/or an amalgamation may in some circumstances be achieved through means other than these statutory provisions, such as a share capital
        exchange, asset acquisition or control, or through contractual arrangements, of an operating business.

      

      

      Shareholders’ Suits. Our Cayman Islands legal counsel is not aware of any reported class action having been brought in a Cayman
          Islands court. Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. In most cases, we will be the proper plaintiff in any claim based on a breach of
          duty owed to us, and a claim against (for example) our officers or directors usually may not be brought by a shareholder. However, based both on Cayman Islands authorities and on English authorities, which would in
            all likelihood be of persuasive authority and be applied by a court in the Cayman Islands, exceptions to the foregoing principle apply in circumstances in which:

      

      

      	

            	•	
              a company is acting, or proposing to act, illegally or beyond the scope of its authority;

            

      

      

      	

            	•	
              the act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been obtained; or

            

      

      

      	

            	•	
              those who control the company are perpetrating a “fraud on the minority.”

            

      

      

      A shareholder may have a direct right of action against us where the individual rights of that shareholder have been infringed or are about to be infringed.

      

      

      Enforcement of Civil Liabilities. The Cayman Islands has a different body of securities laws as compared to the United States and provides less protection to investors. Additionally, Cayman Islands companies may not have
          standing to sue before the Federal courts of the United States.

      

      

      
        
          

      

      We have been advised by our Cayman Islands legal counsel that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against us judgments of courts of the United States
        predicated upon the civil liability provisions of the federal securities laws of the United States or any state; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability
        provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of
        judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a
        competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final
        and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of
        a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands Court may stay enforcement
        proceedings if concurrent proceedings are being brought elsewhere.

      

      

      Special Considerations for Exempted Companies. We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is
          registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except for
          the exemptions and privileges listed below:

          

        

      
        	 	
                •

              	
                an exempted company does not have to file an annual return of its shareholders with the Registrar of Companies;

              

      

      

      

      	

            	•	
              an exempted company’s register of members is not open to inspection;

            

      

      

      	

            	•	
              an exempted company does not have to hold an annual general meeting;

            

      

      

      	

            	•	
              an exempted company may issue shares with no par value;

            

      

      

      	

            	•	
              an exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance);

            

      

      

      	

            	•	
              an exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;

            

      

      

      	

            	•	
              an exempted company may register as a limited duration company; and

            

      

      

      	

            	•	
              an exempted company may register as a segregated portfolio company.

            

      

      

      “Limited liability” means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company (except in exceptional circumstances, such as involving fraud, the
        establishment of an agency relationship or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).

       

         

      
        
          

      

      Our Amended and Restated Memorandum and Articles of Association

       

      

      The Business Combination Article of our amended and restated memorandum and articles of association contains provisions designed to provide certain rights and protections relating to our initial public offering that
        will apply to us until the completion of our partnering transaction. These provisions cannot be amended without a special resolution. As a matter of Cayman Islands law, a resolution is deemed to be a special resolution where it has been approved by
        either (i) at least two-thirds (or any higher threshold specified in a company’s articles of association) of a company’s shareholders at a general meeting for which notice specifying the intention to propose the resolution as a special resolution
        has been given; or (ii) if so authorized by a company’s articles of association, by a unanimous written resolution of all of the company’s shareholders. Our amended and restated memorandum and articles of association provide that special
        resolutions must be approved either by at least two-thirds of our shareholders (i.e., the lowest threshold permissible under Cayman Islands law), or by a unanimous written resolution of all of our shareholders.

      

      

      Our initial shareholders, who collectively beneficially own 20% of our ordinary shares as of the closing of our initial public offering, will participate in any vote to amend our amended and restated memorandum and
        articles of association and will have the discretion to vote in any manner they choose. Specifically, our amended and restated memorandum and articles of association provide, among other things, that:

      

      

      	

            	•	
              If we do not complete our partnering transaction by October 6, 2023, we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten
                business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the trust account (net of
                permitted withdrawals and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including
                the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors, liquidate and
                dissolve, subject in each case to our obligations under Cayman Islands law to provide for claims of creditors and in all cases subject to the requirements of other applicable law;

            

      

      

      	

            	•	
              Prior to our partnering transaction, we may not issue additional securities that would entitle the holders thereof to (i) receive funds from the trust account or (ii) vote as a class with our public shares
                (a) on our partnering transaction or (b) to approve an amendment to our amended and restated memorandum and articles of association to (x) extend the time we have to consummate our partnering transaction beyond October 6, 2023 or (y) amend
                the foregoing provisions;

            

      

      

      
        
          

      

      	

            	•	
              Although we do not intend to enter into our partnering transaction with a partnering candidate that is affiliated with our sponsor, our directors or our executive officers, we are not prohibited from doing
                so. In the event we enter into such a transaction, we, or a committee of independent directors, will obtain an opinion from an independent investment banking firm or an independent accounting firm that such our partnering transaction is
                fair to our company from a financial point of view;

            

      

      

      	

            	•	
              If a shareholder vote on our partnering transaction is not required by law and we do not decide to hold a shareholder vote for business or other legal reasons, we will offer to redeem our public shares
                pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, and will file tender offer documents with the SEC prior to completing our partnering transaction which contain substantially the same financial and other information about our
                partnering transaction and the redemption rights as is required under Regulation 14A of the Exchange Act. Whether or not we maintain our registration under the Exchange Act or our listing on the NYSE, we will provide our public shareholders
                with the opportunity to redeem their public shares by one of the two methods listed above;

            

      

      

      	

            	•	
              So long as we maintain a listing for our securities on the NYSE, the NYSE rules require that we must complete one or more partnering transactions having an aggregate fair market value of at least 80% of the
                value of the assets held in the trust account (excluding the taxes payable on the interest earned on the trust account) at the time of the agreement to enter into our partnering transaction;

            

      

      

      	

            	•	
              If our shareholders approve an amendment to our amended and restated memorandum and articles of association to modify the substance or timing of our obligation to redeem 100% of our public shares if we do not
                complete our partnering transaction by October 6, 2023, or with respect to any other material provisions relating to shareholders’ rights or pre-partnering transaction activity, we will provide our public shareholders with the opportunity
                to redeem all or a portion of their Class A ordinary shares upon such approval at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the trust account, including interest earned on the funds held in the
                trust account (net of permitted withdrawals and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, subject to the limitations described herein; and

            

      

      

      	

            	•	
              We will not effectuate our partnering transaction solely with another blank check company or a similar company with nominal operations.

            

      

      

      In addition, our amended and restated memorandum and articles of association provides that under no circumstances will we redeem our public shares in an amount that would cause our net tangible assets to be less than $5,000,001.

      

      

      The Companies Act permits a company incorporated in the Cayman Islands to amend its memorandum and articles of association with the approval of a special resolution. A company’s articles of association may specify that
        the approval of a higher majority is required but, provided the approval of the required majority is obtained, any Cayman Islands exempted company may amend its memorandum and articles of association regardless of whether its memorandum and
        articles of association provides otherwise. Accordingly, although we could amend any of the provisions relating to our proposed offering, structure and business plan which are contained in our amended and restated memorandum and articles of
        association, we view all of these provisions as binding obligations to our shareholders and neither we, nor our officers or directors, will take any action to amend or waive any of these provisions unless we provide dissenting public shareholders
        with the opportunity to redeem their public shares.

       

         

      
        
          

      

      Certain Anti-Takeover Provisions of Our Amended and Restated Memorandum and Articles of Association

      

      

      Our authorized but unissued ordinary and preference shares are available for future issuances without shareholder approval and could be utilized for a variety of corporate purposes, including
        future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved ordinary and preference shares could render more difficult or discourage an attempt to obtain control of
        us by means of a proxy contest, tender offer, merger or otherwise.

      

      

      Securities Eligible for Future Sale

       

      

      We have 29,744,500 ordinary shares issued and outstanding. Of these shares, the 28,090,000 Class A ordinary shares are freely tradable without restriction or further registration under the
        Securities Act, except for any shares purchased by one of our affiliates within the meaning of Rule 144 under the Securities Act. All of the remaining 1,404,500 founder shares, all 5,412,000 private placement warrants, all 250,000 performance
        shares, and the securities underlying the foregoing, are restricted securities under Rule 144, in that they were issued in private transactions not involving a public offering, and are subject to transfer restrictions as set forth in the prospectus
        for our initial public offering. Upon the closing of the sale of the forward purchase shares and forward purchase warrants, the forward purchase shares, forward purchase warrants and the Class A ordinary shares underlying the forward purchase
        warrants that are purchased will be restricted securities under Rule 144.

      

      

      Rule 144

       

      

      Pursuant to Rule 144, a person who has beneficially owned restricted shares or warrants for at least six months would be entitled to sell their securities provided that (i) such person is not deemed to have been one of
        our affiliates at the time of, or at any time during the three months preceding, a sale and (ii) we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under
        Section 13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale.

      

      

      Persons who have beneficially owned restricted shares or warrants for at least six months but who are our affiliates at the time of, or at any time during the three months preceding, a sale, would be subject to
        additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of:

      

      

      
        
          

      

      	

            	•	
              1% of the total number of ordinary shares then outstanding, which will currently equal 297,445; or

            

      

      

      	

            	•	
              the average weekly reported trading volume of the Class A ordinary shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

            

      

      

      Sales by our affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about us.

      

      

      Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously a shell company.
        However, Rule 144 also includes an important exception to this prohibition if the following conditions are met:

      

      

      	

            	•	
              the issuer of the securities that was formerly a shell company has ceased to be a shell company;

            

      

      

      	

            	•	
              the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;

            

      

      

      	

            	•	
              the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file
                such reports and materials), other than Form 8-K reports; and

            

      

      

      	

            	•	
              at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

            

      

      

      As a result, our initial shareholders will be able to sell their founder shares and our sponsor will be able to sell its private placement warrants, and the securities underlying the foregoing, pursuant to Rule 144
        without registration one year after we have completed our initial partnering transaction.

      

      

      Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies

       

      

      Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination related shell companies) or issuers that have been at any time previously
        a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met:

       

      

      	

            	•	
              the issuer of the securities that was formerly a shell company has ceased to be a shell company;

            

       

      

      	

            	•	
              the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act;

            

       

      

      	

            	•	
              the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file
                such reports and materials), other than Current Reports on Form 8-K; and

            

       

      

      	

            	•	
              at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company.

            

      

      

      As a result, our initial shareholders will be able to sell their founder shares and private placement warrants, as applicable, pursuant to Rule 144 without registration one year after we have
        completed our initial business combination.

      

      

      
        
          

      

      Registration Rights

       

      

      The holders of the founder shares, performance shares, forward purchase shares or private placement warrants, and private placement warrants that may be issued upon conversion of working capital
        loans (and any Class A ordinary shares issuable upon the exercise of the private placement warrants, and private placement warrants may be issued upon conversion of working capital loans and upon conversion of the founder shares and the performance
        shares) are entitled to registration rights pursuant to a registration and shareholder rights agreement requiring us to register such securities for resale. The holders of these securities are entitled to make up to three demands, excluding short
        form demands, that we register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to our completion of our partnering transaction. We will bear the
        expenses incurred in connection with the filing of any such registration statements.

      

      

      Pursuant to the forward purchase agreement we entered into in connection with our initial public offering, we agreed to use our reasonable best efforts (i) to file within 30 days after the closing
        of our partnering transaction a registration statement with the SEC for a secondary offering of the forward purchase shares and the forward purchase warrants (and underlying Class A ordinary shares), (ii) to cause such registration statement to be
        declared effective promptly thereafter but in no event later than 60 days after the initial filing, (iii) to maintain the effectiveness of such registration statement until the earliest of (A) the date on which the forward purchasers or its
        assignees cease to hold the securities covered thereby and (B) the date all of the securities covered thereby can be sold publicly without restriction or limitation under Rule 144 under the Securities Act and (iv) after such registration statement
        is declared effective, cause us to conduct firm commitment underwritten offerings, subject to certain limitations. In addition, the forward purchase agreement provides for certain “piggy-back” registration rights to the holders of forward purchase
        securities to include their securities in other registration statements filed by us.

      

      

      Pursuant to the registration and shareholder rights agreement, our sponsor, upon and following consummation of our partnering transaction, will be entitled to nominate three individuals for
        election to our board of directors, as long as the sponsor holds any securities covered by the registration and shareholder rights agreement.

      

      

      Listing of Securities

       

      

      Our units, Class A ordinary shares and warrants have been approved to be listed on the NYSE under the symbols “CORS.U,” “CORS” and “CORS.WS,” respectively.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00342-of-00352.parquet"}]]